About 84.8% of all AML patients (n = 1116) were characterized by 7 fusion genes KMT2A::MLLT3, KMT2A::MLLT10, KMT2A-PTD, KMT2A::ELL, KMT2A::AFDN, KMT2A::MLLT1, and KMT2A::MLLT11. This evidence concerns the gene KMT2A and acute myeloid leukemia.